Coherus Oncology, Inc.
CHRSAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Apr 24, 2025 | UBS | Ashwani Verma | $1.05(+0%) | $1.04 | TheFly |
| Dec 5, 2024 | Robert W. Baird | Colleen Kusy | $6.00(+246%) | $1.74 | StreetInsider |
| Nov 14, 2022 | J.P. Morgan | $11.00(+41%) | $7.79 | Benzinga | |
| Jun 13, 2022 | UBS | Ashwani Verma | $7.00(+13%) | $6.19 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Guggenheim | maintain | Buy | Aug 7, 2026 |
| Maxim Group | upgrade | Hold →Buy | Sep 4, 2025 |
| HC Wainwright & Co. | maintain | Buy | Apr 29, 2025 |
| UBS | maintain | Neutral | Apr 24, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 23, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 22, 2025 |
| Baird | maintain | Outperform | Dec 5, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 4, 2024 |
| Baird | maintain | Outperform | Nov 8, 2024 |
| HC Wainwright & Co. | maintain | Buy | Nov 7, 2024 |
| HC Wainwright & Co. | maintain | Buy | Sep 16, 2024 |
| UBS | downgrade | Buy →Neutral | Aug 16, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 5, 2024 |
| Baird | maintain | Outperform | Jul 1, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 24, 2024 |
| Truist Securities | maintain | Buy | May 13, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 10, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Mar 14, 2024 |
| Baird | maintain | Outperform | Jan 23, 2024 |
| Truist Securities | maintain | Buy | Jan 23, 2024 |
| HC Wainwright & Co. | maintain | Buy | Dec 27, 2023 |
| HC Wainwright & Co. | maintain | Buy | Dec 7, 2023 |
| Truist Securities | maintain | Buy | Nov 28, 2023 |
Earnings History
| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 5, 2026 | $-0.19 | $-0.25 | $14.3M | $14.4M |
| May 11, 2026 | $-0.25 | $-0.26 | $12.3M | $14.2M |
| Mar 9, 2026 | $-0.34 | $-0.36 | $12.7M | $13.9M |
| Nov 6, 2025 | $-0.33 | $-0.32 | $11.6M | $14.1M |
| Aug 7, 2025 | $-0.34 | $-0.31 | $10.3M | $12.0M |
| May 12, 2025 | $-0.35 | $-0.31 | $7.6M | $61.0M |
| Mar 10, 2025 | $-0.44 | $-0.10 | $54.1M | $44.1M |
| Nov 6, 2024 | $-0.01 | $-0.16 | $70.8M | $59.0M |
News
Coherus Oncology (CHRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coherus Oncology, Inc. (CHRS) Discusses Tagmokitug Interim Clinical Data in Esophageal Cancer Transcript
Coherus Oncology NASDAQ: CHRS presented interim clinical data for tagmokitug, an investigational therapy designed to target CCR8-positive regulatory T cells, in several solid-tumor settings. The company highlighted early activity in esophageal squamous cell carcinoma, or ESCC, and said it plans to expand cohorts and discuss potential regulatory paths with the U.S. Food and Drug Administration.
- 1L ESCC confirmed ORR of 75% irrespective of PD-L1 status, confirmed ORR of 100% for PD-L1- positive, in evaluable patients- -2L ESCC durable clinical benefit observed with a clear dose-response irrespective of PD-L1 status and in PD-1 refractory patients- - Anti-tumor activity demonstrated across five indications and over 120 patients, including HPV-positive head and neck and GI tumors- - Acceptable and manageable safety profile, with no new safety signals to date supports continued developme…
REDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor conferences:
REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9, 2026. Starting at 5:00 p.m. Eastern Daylight Time on November 9, 2026, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug development program evaluating the cytolytic CCR8 antibody with toripalimab and multiple solid tumors on Wednesday, October 28, 2026. Coherus management will host a webcast from 4:30 p.m. to 6:00 p.m. Eastern Daylight Time to discuss the data and provide additional context. The company has invited key opinion l…
Molecular Partners (NASDAQ: MOLN - Get Free Report) and Coherus Oncology (NASDAQ: CHRS - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, valuation, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Molecular
Coherus Oncology (NASDAQ: CHRS - Get Free Report) and Emergent Biosolutions (NYSE: EBS - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings. Analyst Ratings This is a breakdown of
- Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders - - Oppenheimer Initiates a Robust Process with Global Reach for the Benefit of Shareholders -
Coherus Oncology, Inc. (CHRS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
BlackRock Inc. bought a new stake in shares of Coherus Oncology, Inc. (NASDAQ: CHRS) during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 12,003,316 shares of the biotechnology company's stock, valued at approximately $16,805,000. BlackRock Inc. owned about
REDWOOD CITY, Calif., Aug. 31, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be participating in upcoming investor conferences:
– Entitles holders to receive net proceeds from sale of remaining Legacy Biosimilar Assets – – Completes transformation of Coherus Oncology into a fully integrated, innovative immuno-oncology company – REDWOOD CITY, Calif., Aug. 17, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) (“Coherus”, “Coherus Oncology” or the “Company”) today announced a special dividend of contingent value rights (each, a “CVR” and collectively, the “CVRs”), which will be distributed on a pro rata basis t…